| Prev Close | 110.04 |
| Open | 110.00 |
| Day Low/High | 109.39 / 111.62 |
| 52 Wk Low/High | 61.61 / 115.14 |
| Volume | 4.48M |
Abbott Laboratories (ABT)
111.30
1.26
1.15
NYSE
| Exchange | NYSE |
| Shares Outstanding | 1772.36B |
| Market Cap | 195.03B |
| P/E Ratio | 59.65 |
| Div & Yield | N.A. (N.A) |
Latest News
Jim Cramer: 8 Stocks That Benefit the Most If There's Another Modified Lockdown
These companies have spent the last six months preparing for a second lockdown betting it will occur.
Jim Cramer: Health Care Stocks, the Election and the Perfect Setup
Right now, the market is furiously trying to price in a Blue Wave, and the health care sector is getting clobbered. But here's how I think things play out.
Does Abbott Labs Still Pass My Test After Earnings?
Diagnostics revenue grew an impressive 38% due to the necessity of Covid-19 testing.
'Inside Day', Electoral Risk, Banking Stocks, Stimulus Immediately Needed
There is a presidential debate on Thursday. The market is being forced to adjust for renewed potential uncertainty.
Jim Cramer: This Is How Stocks Would Fare Under a President Biden
I don't pick stocks on politics, but was shocked to see how a majority of our Action Alerts PLUS holdings would perform if Joe Biden wins the White House.
Jim Cramer: Better to Mask and Test Than Wait for Vaccine
New rapid tests and the effectiveness of universal mask wearing give hope while we wait on the elusive vaccine.
Jim Cramer: Fly Ahead of the Pack on Boeing
People want to wait and see on this beleaguered aviation name, but I don't think you can do that. Here's why.
Jim Cramer: You Heard the Ugly of the Debate. Here's the Good.
Neither candidate seems to be the enemy of the market -- at least not yet.
Abbott Labs Stock Could Still Slip Lower
Let's review the charts and indicators.
Jim Cramer: Abbott's Rapid Covid-19 Test and My Super Bowl Dreams
Abbott Labs can bring back some normalcy to this country -- and the world -- with its BinaxNOW rapid antigen test along with its amazing Navica app.
This Dividend Stock's Got the Right Medicine for Investors
AbbVie stock is a rare combination of value, growth, and yield, making it a unique pick in the health care sector.
Charting the Best Hotels in the Sector
We grade Choice Hotels, Hilton and Marriott, and check on the opportunities each offers.
Rapid Test, Rapid Dow Rally?
Here's what I expect to happen to the market near term off this potentially game-changing development.
Jim Cramer: Abbott Labs and the Rally in Travel
ABT will end the issues of flying and cruising. Of course it's another story when you get there. But boarding will be solved.
If You Like Laggards, Here Are 3 to Consider
These companies will benefit immensely as the country experiences a burst of economic growth.
Market Continues Higher in Front of Big Stock Splits and Dow Rebalancing
There is major rotational action taking place but the flood of liquidity is preventing any real downside from developing.
Vaccine Chills, Divergent Trails, Fed-flation, Walmart and TikTok: Market Recon
Plus, Veeva Systems reports stellar results and ups its guidance.
Rotation Unravels Speculative Plays
Speculative trading in lower-priced stocks has dried up and the small caps have been much tougher.
Jim Cramer: Here Comes the Biggest Test Yet
As the president pins all hopes on a Covid vaccine and shuns tried-and-true prevention efforts, Abbott is offering a rapid test that could be a game changer.
There Are Several Different Market Themes Now
One is Abbott Labs' announcement of a quick and cheap Covid test.
Abbott Labs Soars to New Heights: The Stock's Next Technical Targets
Here's where ABT could be headed next.
Focus on Rotation and Not the Direction of the Indices
It isn't just valuation that is likely to drive rotational action.
Jim Cramer: All These Stocks Are Not Quite 'Dow and Out'
Let's look at the Dow Jones' swapping of Exxon for Salesforce, Pfizer for Amgen and Raytheon for Honeywell.
Jim Cramer: 'Excuse Selling'
Let's go over five excuses so you know and are armed with them when they are used and make you faint and weak-handed.
Jim Cramer: An Analyst's Dream
All we have to do is take our cue from companies that boosted their forecasts but their stocks did nothing.
We'll Be Checking on These Corporate Earnings Next Week
Next week the June quarter earnings season maelstrom kicks off with 115 companies, including 32 S&P 500 constituents, reporting their latest quarterly results. In recent days we've seen a number of companies up their outlook for the quarter but we'v...
I Wouldn't Buy Pfizer Shares on This Pop
I would wait until the next down day, and there will be one.
